Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 10 December 2007. doi:10.1136/hrt.2007.132662
Heart 2008;94:844-847
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

ORIGINAL ARTICLES

Interventional cardiology

Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale

S P Schoen1, A Boscheri1, S A Lange1, M U Braun1, J Fuhrmann1, U Kappert2, R H Strasser1

1 Department of Cardiology, University of Dresden, Germany
2 Department of Cardiosurgery, University of Dresden, Germany

Dr S P Schoen, Department of Cardiology, Heart Centre, University of Dresden, Fetscherstr 76, 01307 Dresden, Germany; cardiology{at}email.de

ABSTRACT

Background: In recent years percutaneous, transcatheter closure of atrial septal defects (ASD) or patent foramen ovale (PFO) was introduced into clinical practice.

Objective: To investigate the functional effects on heart valves caused by an interatrial closure device.

Methods and results: Between 2001 and 2006, 240 consecutive patients underwent percutaneous closure of an ASD or a PFO. Heart valve functions were defined by transoesophageal echocardiography before implantation and 3, 6 and 12 months after defect closure. A successful implantation procedure was performed in 98% of patients. Sufficient closure without residual shunt was achieved in 89% of patients with ASD and in 92% of patients with PFO. An overall major complication rate of 0.8% was apparent during the observation time (mean (SD) 27 (15) months). Long-term follow-up disclosed newly developed or worsened aortic valve regurgitation (AR) in 9% of patients with ASD and in 10% of patients with PFO. A potential cause for developing AR may be overgrowth of the device by tissue, leading to changes in interatrial septal geometry and traction on the root of the non-coronary aortic cusp.

Conclusion: AR occurred in 9% of patients with closed ASD and in 10% of patients with closed PFO. Indication for closure should consider this potential complication despite an otherwise safe interventional procedure.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Wohrle, J., Kochs, M., Spiess, J., Nusser, T., Hombach, V., Merkle, N. (2009). Impact of Percutaneous Device Implantation for Closure of Patent Foramen Ovale on Valve Insufficiencies. Circulation 119: 3002-3008 [Abstract] [Full Text]  
  • McElhinney, D. B. (2009). Patent Foramen Ovale Closure: Let's Keep the Heart in Mind. Circulation 119: 2967-2968 [Full Text]  
  • Meier, B. (2009). Stroke and migraine: a cardiologist's headache. Heart 95: 595-602 [Full Text]  
  • Wahl, A, Meier, B (2009). Patent foramen ovale and ventricular septal defect closure. Heart 95: 70-82 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.